Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development

ABSTRACT: Rituximab (MabThera(®)/Rituxan(®)), a chimeric murine/human monoclonal antibody that binds specifically to the transmembrane antigen CD20, was the first therapeutic antibody to enter clinical practice for the treatment of cancer. As monotherapy and in combination with chemotherapy, rituxim...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Andrew, Berge, Claude, Boehnke, Axel, Dadabhoy, Anjum, Lugtenburg, Pieternella, Rule, Simon, Rummel, Mathias, McIntyre, Christine, Smith, Rodney, Badoux, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656720/
https://www.ncbi.nlm.nih.gov/pubmed/28983819
http://dx.doi.org/10.1007/s12325-017-0610-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656720/
https://www.ncbi.nlm.nih.gov/pubmed/28983819
http://dx.doi.org/10.1007/s12325-017-0610-z

Ejemplares similares